US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bms_opdivo_cleared_for_monthly_use_1226100GlaxoSmithKline has announced that Emma Walmsley will take over from current chief executive Andrew Witty following his retirement at the end of March next year. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/gsk_names_new_chief_executive_1137962Gilead says the study was underpowered and so statistically meaningful conclusions could not be drawn - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/who_prematurely_publishes_remdesivir_results_1338863Boehringer's stake in the firm equates to around 16.4% - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/boehringer_to_sell_stake_in_hikma_1342700Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/teva_divests_uk,_ireland_assets_1154632The drug's use has, however, been restricted to reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding in the gastrointestinal tract - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nice_backs_portolas_ondexxya_1349854Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_turns_down_takedas_advances_1232652Shire's proposal to acquire Baxalta for around $32 billion and create "the global leader in rare diseases" has now been approved by both sets of shareholders. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shareholders_approve_$32bn_shirebaxalta_marriage_1032351AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astrazeneca_sells_atacand_rights_to_cheplapharm_1245495The novel gene therapy is being developed for the lysosomal storage disease Sanfilippo syndrome type A (MPS IIIA) - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/prime_status_for_abeonas_gene_therapy_1320870
